We are live on ! Find out more
AGIO icon

Agios Pharmaceuticals
AGIO

120 hedge funds and large institutions have $1.5B invested in Agios Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 32 increasing their positions, 33 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

124% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 17

39% more capital invested

Capital invested by funds: $1.08B → $1.5B (+$420M)

21% more funds holding

Funds holding: 99 → 120 (+21)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

3% less repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 33

51% less call options, than puts

Call options by funds: $6.06M | Put options by funds: $12.3M

Holders
120
Holders Change
+21
Holders Change %
+21.21%
% of All Funds
3.48%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.17%
New
38
Increased
32
Reduced
33
Closed
17
Calls
$6.06M
Puts
$12.3M
Net Calls
-$6.23M
Net Calls Change
-$5.35M

Top Buyers

Rank Fund Capital Flow
1
BB
BB Biotech
Switzerland
+$59.7M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$24.8M
3
State Street
State Street
Massachusetts
+$16M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$9.52M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.85M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$46.7M
2
TRV
Third Rock Ventures
Massachusetts
-$35.6M
3
HLA
Hamilton Lane Advisors
Pennsylvania
-$11.4M
4
SOMRS
State of Michigan Retirement System
Michigan
-$10.9M
5
GE
General Electric
Ohio
-$7.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
BIT
26
BlackRock Institutional Trust
California
$8.62M -$485K -11,249 -7%
UBS AM
27
UBS AM
Illinois
$8.45M +$5.94M +137,800 New
QF
28
QVT Financial
New York
$8.35M +$302K +7,000 +5%
HCM
29
Hodges Capital Management
Texas
$7.97M +$5.6M +130,000 New
OM
30
Opaleye Management
Massachusetts
$6.96M -$64.7K -1,500 -1%
PHS
31
PFM Health Sciences
California
$6.64M +$4.67M +108,241 New
Deutsche Bank
32
Deutsche Bank
Germany
$6.14M +$381K +8,839 +10%
CAM
33
Cormorant Asset Management
Massachusetts
$6.13M +$4.31M +100,000 New
CCI
34
Columbus Circle Investors
$4.93M +$3.46M +80,314 New
Bank of New York Mellon
35
Bank of New York Mellon
New York
$4.8M +$5K +116 +0.1%
GACM
36
Green Arrow Capital Management
New York
$4.6M +$2.03M +47,097 +169%
GC
37
Guggenheim Capital
Illinois
$4.54M +$31.3K +727 +1%
BG
38
BlackRock Group
United Kingdom
$4.05M +$933K +21,638 +49%
Axa
39
Axa
France
$3.83M -$17.2K -400 -0.6%
Geode Capital Management
40
Geode Capital Management
Massachusetts
$3.77M +$88.7K +2,057 +3%
BIM
41
BlackRock Investment Management
Delaware
$3.37M +$398K +9,225 +20%
ACM
42
Atika Capital Management
New York
$3.31M +$1.81M +42,000 +350%
MSA
43
Mason Street Advisors
Wisconsin
$3.29M – – –
CS
44
Credit Suisse
Switzerland
$3.27M +$1.7M +39,419 +283%
TCIM
45
TIAA CREF Investment Management
New York
$3.05M -$46.2K -1,072 -2%
RG
46
Redmile Group
California
$3.02M +$2.12M +49,200 New
ZDA
47
Zweig-DiMenna Associates
New York
$2.85M +$2M +46,483 New
HJMC
48
Hellman Jordan Management Company
Massachusetts
$2.45M +$1.72M +40,000 New
WJA
49
Williams Jones & Associates
New York
$2.31M +$878K +20,375 +118%
TCM
50
Tekla Capital Management
Massachusetts
$2.15M +$1.51M +35,000 New
1
2
3 4 5

AGIO Hedge Fund Activity: Q3 2014 in Review

120 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q3 2014, worth a combined $1.5B — up 39% from $1.08B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new AGIO positions and 17 closed out — a net gain of 21 holders — while 32 added to existing stakes and 33 trimmed.

The largest buyer was BB Biotech, adding an estimated $59.7M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $46.7M sold.

  • 120 institutional investors held Agios Pharmaceuticals (AGIO) as of Q3 2014, up from 99 in Q2 2014.
  • Funds reported $1.5B of Agios Pharmaceuticals stock for Q3 2014, up 39% quarter-over-quarter.
  • 38 funds opened new Agios Pharmaceuticals positions in Q3 2014 and 17 closed out, a net change of +21 holders.
  • The largest Agios Pharmaceuticals buyer in Q3 2014 was BB Biotech, an estimated $59.7M added.
  • The largest Agios Pharmaceuticals seller in Q3 2014 was T. Rowe Price Associates, an estimated $46.7M sold.

Based on aggregated 13F filings for Q3 2014.